Interventional Endocrinology · San Diego
A scar-free, in-office alternative to thyroid surgery: radiofrequency ablation (RFA) shrinks benign thyroid nodules using image-guided heat under local anesthesia — with published outcomes from our own practice.
Radiofrequency ablation uses a thin, internally cooled electrode, placed through the skin under continuous ultrasound guidance, to deliver heat directly into a thyroid nodule. The heat destroys the nodule tissue, and over the following weeks and months the body gradually clears it away, so the nodule shrinks.
RFA does not cut the nodule out. Instead of removing thyroid tissue surgically, it treats the nodule in place and leaves the surrounding healthy thyroid untouched. That is the central difference from an operation, and it is why most people keep normal thyroid function afterward and avoid a lifelong thyroid hormone pill.
RFA is well established. It has been a routine treatment for benign thyroid nodules for years in high-volume centers internationally, particularly in South Korea and parts of Europe, where published series report durable volume reduction of roughly 80–90% beyond three years after a single session, with low regrowth and very low rates of serious complications. In the United States, adoption began in academic centers and is now reaching community practice — which is where our own experience comes in.
The technique we use is the trans-isthmic moving-shot approach under real-time ultrasound — the same method described in the international literature. Here is what actually happens during a treatment.
After written consent, the front of the neck is numbed with lidocaine and epinephrine. You stay awake and comfortable throughout — there is no general anesthesia and no breathing tube.
Under continuous ultrasound, the RFA electrode is advanced toward the nodule using a trans-isthmic approach — entering across the isthmus so the needle path stays controlled and away from critical structures.
Radiofrequency energy is delivered in small, controlled zones, moving through the nodule until all safely accessible parts have been treated — rather than heating a single fixed spot.
If a nodule has a large fluid (cystic) component, the fluid is drained with a fine cannula under ultrasound immediately before ablation, so the solid wall can then be treated effectively.
Equipment. We use an internally cooled monopolar RFA electrode (RF Medical ThyBlate, 18-gauge, 10 mm active tip). The procedure is performed in the office; most patients go home the same day and return to normal activity quickly.
For a benign nodule, surgery (removing part or all of the thyroid) and RFA both relieve symptoms — but they get there very differently. RFA is a gland-preserving alternative that avoids the main downsides of an operation.
| Radiofrequency ablation | Thyroid surgery | |
|---|---|---|
| Incision & scar | None — needle through the skin | Neck incision and permanent scar |
| Anesthesia | Local only, awake | General anesthesia |
| Hospital stay | None — outpatient, home same day | Often overnight or day-surgery admission |
| Thyroid function | Preserved in nearly all patients | Lobectomy or total removal can require lifelong thyroid hormone |
| The nodule | Shrinks over months; tissue stays in place | Removed entirely |
| Recovery | Quick — back to normal activity fast | Surgical recovery period |
| Repeatable | Can be repeated if needed | Re-operation is more complex |
An estimated 30,000–50,000 U.S. patients undergo surgery each year for benign thyroid disease. RFA offers a gland-preserving alternative that avoids general anesthesia, cervical scarring, hospitalization, and the long-term consequences of removing the thyroid — extending treatment to patients who decline surgery or cannot safely undergo it.
Most RFA information online comes from large overseas academic centers. The data below is ours — 118 consecutive patients with cytologically benign nodules, treated in a community endocrine practice and presented at ENDO 2026. These are six-month outcomes; longer-term follow-up is ongoing.
101 of 118 patients reached a favorable response; 33 of 118 reached near-complete ablation. All patients were symptomatic at baseline; 71 had complete resolution of their presenting symptoms by six months, with substantial improvement in nearly all others.
| Nodule type | N | Baseline volume | Mean VRR |
|---|---|---|---|
| Solid / predominantly solid | 95 | 15.6 mL | 71.4% |
| Mixed cystic–solid | 23 | 45.6 mL | 85.8% |
| Overall cohort | 118 | 21.4 mL | 75.0% |
Mixed cystic–solid nodules responded better than predominantly solid nodules (85.8% vs 71.4% mean VRR, p < 0.05). Cystic components were drained immediately before ablation.
Across all 118 patients, there were no major complications — no permanent voice change, no structural damage, and no hypothyroidism caused by the procedure. The side effects that did occur were minor and resolved.
| Event | N (%) | Course |
|---|---|---|
| Transient voice change | 11 (9.3%) | Full resolution |
| Fever | 7 (5.9%) | Self-limited; 1 patient needed a 5-day course of antibiotics |
| Pain requiring prescription-strength analgesia | 1 (0.8%) | Self-limited |
| Hematoma lasting > 1 week | 0 (0%) | None observed |
| Major complications | 0 (0%) | None observed (95% CI 0–3.1%) |
This safety profile is consistent with the international long-term series from Italy, Spain, and South Korea, which report severe-complication rates well under 1%.
RFA is low-risk in experienced hands, but it is a medical procedure with real trade-offs. Here is the straight version — the things every candidate should understand before deciding.
RFA reduces a nodule’s size; it does not take it out. Treated tissue stays in place and clears gradually. Most nodules shrink substantially, but not to zero.
RFA is only for nodules confirmed benign on biopsy. It is not a treatment for thyroid cancer or for nodules with suspicious or indeterminate cytology.
A minority of nodules can partially regrow over years and may need a repeat session. Long-term follow-up with ultrasound is part of the plan.
Pain, a sensation of warmth, or a short-lived voice change can occur. In our cohort these resolved, but they are real and worth expecting.
RFA outcomes are operator-dependent. Volume reduction and safety are best in experienced, high-volume hands — technique and judgment matter.
Location, size, composition, and your overall thyroid picture all affect whether RFA is the right choice. Some nodules are better served by surgery or surveillance.
Start with a thyroid nodule evaluation at Diabetes & Endocrine Specialists — we confirm the diagnosis and tell you honestly whether RFA is appropriate.
Request an evaluation